Featured
Featured posts

0 13068

Among the many segments of the marijuana industry that we cover, CBD has taken on a big role not only for its biotech-based applications but also for its uses outside of the health sciences sector. And with the growth that the market as a whole could be set to see, CBD companies are definitely in the spotlight for the foreseeable future.

One Marijuana Stock that we’ve been reporting on since late last year has been Ubiquitech Software Corp (UBQU).  Now don’t let the name fool you, this company, through its subsidiary HempLife Today™ is breaking barriers with its CBD brand while also hitting major milestones over the last year.  What could be best of all is that 2017 could already have the stage set for yet another record setting period in (UBQU)’s company history.

Earlier this morning the company put out preliminary guidance on what it is anticipating to be a banner year ahead.  According to the release, the company anticipates that revenues for the year ending November 30, 2017 will increase over 55% from $3,493,113, which was reported in the annual period ended November 30, 2016 to approximately $5,450,000.

Ubiquitech Gives Fiscal Year 2017 Revenue Guidance; Anticipates 55% Year Over Year Increase To $5,450,000

“We are very pleased with the progress we have made and we will continue to do everything within our power to keep our company relevant and growing” said James Ballas, CEO “With the quality of our products, our marketing, customer support and satisfaction, and our dynamic thinking, we will continue this growth through 2017 and into 2018, which we are already planning big things for, and this is the thinking that will take our revenues to even higher gains as we continue. It’s a very exciting industry and we don’t plan to stop until the CannazALL brand is a household word.”

(UBQU) is no stranger to growth.  If you’re just pulling up the company’s other headlines, you’ll already notice major strides being made on the product end. Toward the beginning of the year, the company announced that it had concluded negotiations and reached an agreement to expand its hemp growing capabilities through an additional 140 acres of available hemp operations. They’ve also expanded their current product line to include brand new offerings.

But back to growth…Had this been a random company with its first press release in history, we might be a bit skeptical but (UBQU) has already proven its ability to run a multi-million dollar business that has managed to grow significantly just within the last year alone. On top of bullish guidance for the year ahead, (UBQU) is also coming off of a strong year and noticeable earnings growth.

Revenues for the last quarter increased to $1,225,015 and to $3,493,113 for the year. But what’s more is that net income increased over 700% from the previous year to $334,350 from $39,651 in 2015. First quarter guidance has already come in bullish on its own with the company expecting revenues for the quarter ended February 28, 2017 to increase over 50% from $697,640 in the first quarter of last year to approximately $1,050,000.

Of course this is just initial guidance and with the year ahead, nothing is set in stone. But one thing is certain and that based on the last releases from the company, (UBQU) has set itself on a growth trend.  So this bullish guidance could be shedding some light on what’s to come for this company in the very near term.

The opportunity for taking advantage of the growth that CBD is beginning to see, could be important to take into consideration.  We’ve previously written about this market and how it could be on a path for growth.  Figures estimate that the CBD market will grow to a $2.1 billion market in sales by 2020. That’s a 700% increase from 2016.  Think about this for a moment: (UBQU) is already growing and is expecting to continue this growth to the tune of 50+% for the year according to today’s announcement…this is all going to happen during a time where the CBD industry as a whole is also anticipating significant growth. Having already come off of a banner year, we think that preliminary guidance from the company would suggest that this is something to be paying close attention to moving into the coming weeks/months/quarters.

Again, you can access today’s (UBQU) news here:

Ubiquitech Gives Fiscal Year 2017 Revenue Guidance; Anticipates 55% Year Over Year Increase To $5,450,000

Pursuant to an agreement between MAPH and Ubiquitech Software Corp., we were hired for a period beginning November 11 2016 and ending May 11, 2017 to publicly disseminate information about (UBQU) including on the Website and other media including Facebook and Twitter. We are being paid $0 (CASH) for or were paid “10 million” shares of restricted common shares. We may buy or sell additional shares of (UBQU) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Full Disclaimer Here

 

 

 

0 3141

Canada is set to make history this week by tabling legislation that would make the nation the first G-7 country to legalize recreational cannabis.

This development has captured the attention of the market and many investors are focusing on companies levered to this opportunity. We want to highlight two Canadian companies that investors should be monitoring closely.

OrganiGram Announces LOI with Trauma Healing Centers

Organigram Holdings (OGI.V) (OGRMF), a licensed medical cannabis producer in Canada announced that it entered a letter of intent to acquire all the issued and outstanding shares of Trauma Healing Centers Incorporated. Under the terms of the LOI, Organigram will issue 719,425 common shares at $2.78 per share to the company.

Trauma Healing Centers currently services over 3,500 patients across 7 Canadian locations and it has plans to open 7 more locations. The company specializes in medical cannabis assessment and prescribing. Trauma sees patients on a referral basis and offers a multi-disciplinary approach to healing chronic conditions.

Trauma Healing Centers will continue to operate independently by providing referrals based on client need to any licensed producer in Canada. The company is the only organization to have a multi-disciplinary designation with Blue Cross for military and RCMP veteran clients.

We favorable on this development due to the potential synergies between the two companies. Also, the $2 million purchase price is attractive when compared to similar transactions. OrganiGram has rallied off its recent lows and this is a company that should be on every investor’s radar.

Canabo Announces Groundbreaking Results

On Friday, Canabo Medical (CMM.V: TSX Venture) (CAMDF: OTCQB) released the results of an observational study that connected doctor-supervised medical cannabis treatments to a decrease in benzodiazepine reliance among Canadian patients.

Research conducted over the past year revealed that 40% of patients who were prescribed medical cannabis to treat pain and anxiety eliminated the use of benzodiazepines within 90 days. The number of patients that stopped using benzodiazepines increased to 45% within a year of cannabis treatment.

 

0 4242

A recent proposal aims to legalize medical marijuana in North Carolina. The bill lays out the development of a medical marijuana supply system and aims to create a program administered by the UNC system called the North Carolina Cannabis Research Program. The program would conduct studies to determine the safety and efficacy of cannabis as medical treatment and then develop guidelines for the appropriate physician administration and patient use of medical cannabis.

The political director of the marijuana advocacy group NORML, Justin Strekal, said the proposal is comprehensive and includes a long list of conditions that doctors could prescribe marijuana to treat. He stated, “Some other states have gone a much more conservative approach in terms of what they will consider marijuana to be a treatment for.” Strekal said there are states that only legalize cannabidiol, or CBD (oil derived from a strain of marijuana without psychoactive effects).

Strekal said, “The CBD-only is really great at treating the kids with refractory epilepsy, but as far as the much more holistic approach that can be used to treat a whole host of ailments, it’s important to have access to the whole plant. So, as far as medical marijuana bills go, we’re very happy with what’s being introduced in North Carolina.” But the federal administration and U.S. Attorney General Jeff Sessions have been increasingly critical of states legalizing marijuana in recent months.

He recently said, “I, as you know, am dubious about marijuana. States can pass whatever laws they choose, but I’m not sure we’re going to be a better, healthier nation if we have marijuana being sold on every corner grocery store.” Whether Sessions and the new administration will actually enforce the federal status of marijuana remains unclear. Strekal said data suggests legalization of medical marijuana could reduce opioid dependency in the state.

Research from the Johns Hopkins Bloomberg School of Public Health and the Philadelphia Veterans Affairs Medical Center found the annual number of deaths from prescription drug overdose is 25% lower in states that have legalized medical marijuana. Strekal said, “The data is very conclusive that marijuana can be a pathway out of addiction rather a gateway in.”

Executive director of Drug Free America Foundation Inc., Calvina Fay, said she doesn’t think the proliferation of marijuana reduces drug-related deaths and overdoses. “Is there a state that has reduced their opioid problem and legalized marijuana? Yeah, I’m sure there is,” she said. “But there’s no proof that marijuana is the cause of that.”

In a speech to Virginia law enforcement in March, Sessions said marijuana proliferation will not staunch the effects of the opioid crisis. Sessions stated, “I am astonished to hear people suggest that we can solve our heroin crisis by legalizing marijuana; so people can trade one life-wrecking dependency for another that’s only slightly less awful.”

However, criticisms of medical marijuana are outdated and not based on scientific fact, Strekal said. He stated, “To maintain the same classification of marijuana in the realm of heroin is absolutely absurd. It’s unfounded, and it’s unfathomable to deny patients access to a substance that will alleviate their suffering.”

0 1121

University of Minnesota students may do double-takes this summer if they spot what looks like marijuana plants growing on the agricultural testing fields at the St. Paul campus. However, the dark green foliage with jagged leaves will actually be industrial hemp, a close look-alike and cousin to marijuana that’s useless for getting high but potentially valuable for certain foods, cosmetics, and oil.

There will be signs posted to indicate that the plants are a hemp experiment and not a drug. The industrial hemp is part of a pilot program regulated by the Minnesota Department of Agriculture that’s now beginning its second year and has generated surprising interest. Last year, seven producers planted about 37 acres of the crop in the state. In 2017, 42 growers will be planting more than 2,100 acres in 26 counties.

Minnesota Department of Agriculture assistant commissioner, Andrea Vaubel, attributes some of the interest to greater public and farmer realization that industrial hemp is a legitimate crop, and that it’s different from medical hemp or cannabis. Industrial hemp is the same plant, she said, but its delta-9 THC level (which gives marijuana its kick) is less than 0.3%. “You’d have to smoke a whole field of it, and all you’d get is a headache,” she said.

Though industrial hemp has no value as a drug, it is still considered a Schedule 1 narcotic under the federal Controlled Substances Act and has been illegal to grow since the 1940s. However, the 2014 Farm Bill allowed states to begin pilot programs to raise industrial hemp as long as they had corresponding laws to regulate it. About half of the states have done so or are moving in that direction.

Studying the growth, cultivation, and marketing of industrial hemp is the goal of the state’s pilot program, Vaubel said. “We really want to understand if this is a viable crop for Minnesota, and are there markets out there for farmers to capitalize on,” she said. “So far we think there are.” Because of federal restrictions, Minnesota producers ordering industrial hemp seeds must have them delivered to the state agriculture department, which inspects and tests them. The growers also need to apply for state permits, pass criminal background checks, and agree to various other conditions during the season and after the hemp is harvested.

University of Minnesota students may do double-takes this summer if they spot what looks like marijuana plants growing on the agricultural testing fields at the St. Paul campus. However, the dark green foliage with jagged leaves will actually be industrial hemp, a close look-alike and cousin to marijuana that’s useless for getting high but potentially valuable for certain foods, cosmetics, and oil.

There will be signs posted to indicate that the plants are a hemp experiment and not a drug. The industrial hemp is part of a pilot program regulated by the Minnesota Department of Agriculture that’s now beginning its second year and has generated surprising interest. Last year, seven producers planted about 37 acres of the crop in the state. In 2017, 42 growers will be planting more than 2,100 acres in 26 counties.

Minnesota Department of Agriculture assistant commissioner, Andrea Vaubel, attributes some of the interest to greater public and farmer realization that industrial hemp is a legitimate crop, and that it’s different from medical hemp or cannabis. Industrial hemp is the same plant, she said, but its delta-9 THC level (which gives marijuana its kick) is less than 0.3%. “You’d have to smoke a whole field of it, and all you’d get is a headache,” she said.

Though industrial hemp has no value as a drug, it is still considered a Schedule 1 narcotic under the federal Controlled Substances Act and has been illegal to grow since the 1940s. However, the 2014 Farm Bill allowed states to begin pilot programs to raise industrial hemp as long as they had corresponding laws to regulate it. About half of the states have done so or are moving in that direction.

Studying the growth, cultivation, and marketing of industrial hemp is the goal of the state’s pilot program, Vaubel said. “We really want to understand if this is a viable crop for Minnesota, and are there markets out there for farmers to capitalize on,” she said. “So far we think there are.” Because of federal restrictions, Minnesota producers ordering industrial hemp seeds must have them delivered to the state agriculture department, which inspects and tests them. The growers also need to apply for state permits, pass criminal background checks, and agree to various other conditions during the season and after the hemp is harvested.

0 1218

A recent court ruling is allowing Arizona colleges and universities to ban medical marijuana on campuses, but legislators cannot make it a crime. The medical marijuana law approved by Arizona voters in 2010 permitted cardholders to possess small amounts of marijuana, but it banned possession in prisons and schools.

The recent ruling struck down a 2012 decision by the Legislature to expand the off-limits list by adding college and university campuses. However, the Court of Appeals ruling said colleges and universities can still forbid possession of medical marijuana under their own rules. It said the 2012 move by the state to forbid marijuana on campuses violated the Arizona Constitution’s protections for voter-approved laws.

Expanding the list of places where medical marijuana is banned doesn’t “further the purpose” of the voter-approved medical marijuana law and even “eliminates some of its protections,” Judge Peter Swann wrote in the ruling. The decision overturned a medical marijuana cardholder’s 2015 conviction for possession of a small quantity of pot in his Arizona State University dorm room.

ASU police found the man’s marijuana card in his wallet and got a warrant to search his room after the man was arrested while sitting on a campus street. Authorities say the man told an officer he had marijuana in his room. Spokesman Ryan Anderson said the Arizona attorney general’s office was disappointed by the recent ruling, but had not decided whether to appeal it to the state Supreme Court.

The state had argued that permitting marijuana use on campuses would jeopardize federal funding for colleges and universities. However, the ruling said the state and other landowners still can regulate what items or materials are taken onto their property, so a person violating an educational institution’s restrictions could be removed from the property or charged with trespassing.

Swann wrote, “If the state finds it necessary to protect federal funding by prohibiting medical marijuana on public college and university campuses, then the medical marijuana law does not stop it from creating such policies. Nor does the law prohibit the Legislature from enacting non-criminal statutes to ensure the absence of medical marijuana on college and university campuses.”

0 3512

Texas is one step closer to eradicating the criminal penalties associated with minor marijuana possession. The House Criminal Jurisprudence Committee recently put its seal of approval on a proposal (House Bill 81) that would allow police all over the state to simply slap those people caught in possession of up to an ounce of weed with a small fine instead of dragging them to jail. The state currently deems this offense a Class B misdemeanor, which carries the potential for marijuana offenders to serve up to six months behind bars.

To ensure the proposal made its way through the first phase of the legislative process, Representative Joe Moody, who also Chairs the committee, was forced to amend the language in a manner that allows judges the right to hit habitual pot offenders with a Class C misdemeanor. Moody stated, “If you’re going to be a frequent customer, you will be moved into the criminal arena.” The proposal is now set to go before the Calendars Committee, which has the power to decide if the measure will get a fair shot in front of the full House.

The bad news is that one of the “No” votes came from Republican Todd Hunter, who just so happens to oversee the Calendars Committee. Therefore, it is distinctly possible that his prejudice toward the bill could stop it from being heard on the House floor altogether. However, marijuana advocates hope that Hunter will leave his personal opinions out of this debate and do the right thing.

Heather Fazio, a spokesperson for Texans for Responsible Marijuana Policy stated, “The state’s current policy of arresting and jailing people for simple marijuana possession is completely unwarranted. Law enforcement officials’ time and limited resources would be better spent addressing serious crimes. No one should be saddled with a lifelong criminal record simply for possessing a substance that is less harmful than alcohol.”

Marijuana Stocks

Marijuana Testing labs are the mystery of the marijuana / cannabis industry.  Marijuana Stocks / Cannabis Companies rely on these labs to determine the level of THC in their products or give them a pass with regards to mold, pests, or pesticides.  The problem is that not all labs are created equal.  The labs themselves aren’t inspected or graded by any agencies and customers have no idea whether products were tested at a reputable lab.  Some believe that the problem is standardization, but there are plenty of state standards.  The real problem is enforcement.

Marijuana consumers tend to equate THC levels with price.  They believe if an edible has a low THC level, it should be cheaper and conversely, if it has a high THC level, it should cost more.  They are looking for more bang for their buck.  Can I get something with 25 mg of THC as cheaply as possible?  The producers know this is just plain wrong.  The process for extracting THC is the same whether the amount is small or not

Many customers prefer a smaller level of THC in order to go about their day without being extremely impaired.  However, because of this developing value trend, some producers are incentivized to get their products listed with higher THC levels and some labs are willing to help them get there.

Dylan Hirsch, executive vice president of a lab corporation said, “Many of the labs will sometimes say they can get better results. It can be so subjective for results on THC.” Sometimes, it’s the growers who are unscrupulous.  They may bring a different product than their own to the lab for testing, one that could have higher THC.  He stated, “There is no assurance that what the lab tested and what they are now selling to someone else is the same product.  Hirsch suggested that there needs to be a tighter supply chain.

Part of the challenge is that the lab’s business model makes it difficult to be profitable.  The machinery is expensive and their staff scientists are well-paid professionals.  For example, testing equipment may cost $600,000, but then they may only be testing 2 samples a day for maybe $100 each.  Hirsch also pointed out that the lab may have expensive testing equipment, but then the testers might not be that great.

Garyn Angel, CEO an infuser machine company, said that different testers give different results.  He believes that another part of the problem is that there are no standard operating procedures for testing marijuana and infused products.  Angel said, “Everything in science works on standard operating procedures.  True science is repeatable.  Testing cannabinoids though is not like testing blood.”  He believes the problem is that the labs don’t want to share their methods and feel it is proprietary because of the competition among labs.

0 1142

NFL players are banned from using the marijuana for any purposes under the existing collective bargaining agreement, even in states where it is legal. Under that agreement, players who test positive for marijuana must enter a substance abuse program. Multiple violations lead to fines, game suspensions, and banishment from the league.

Former NFL players have been increasingly vocal in their criticism of the ban in recent years, saying that medical marijuana is a safe alternative to the powerful prescription opiates routinely prescribed to NFL players for pain. Documents obtained by The Post earlier this year show that NFL teams are heavy users of prescription pain medications, averaging about “six to seven pain pills or injections a week per player over the course of a typical NFL season.”

There’s little evidence that opiates work for the chronic aches and pains often suffered by football players. But there’s strong evidence that anyone, NFL pro or otherwise, who uses opiates on a long-term basis is putting themselves at serious risk for drug dependency, overdose, and death. A 2014 review of 39 studies investigating the efficacy of opiate painkillers for chronic pain found that “evidence on long-term opioid therapy for chronic pain is very limited but suggests an increased risk of serious harms that appear to be dose-dependent.” In other words, there’s little evidence of benefit for treating chronic pain with opioids, but a there is a real risk of harm.

The implications of this finding shouldn’t be understated, for either NFL players or the public. Opiate painkillers, like the ones prescribed in bulk by the NFL, kill over 15,000 people a year via overdose. No death from a marijuana overdose has been reported, according to the DEA. On the other hand, chronic pain is one of the conditions that marijuana has been shown to be effective at treating. Earlier this year the National Academies of Sciences, Engineering and Medicine published an expansive literature review, spanning decades of research, showing “substantial evidence that cannabis is an effective treatment for chronic pain in adults.”

The NFL, in other words, is pumping its players full of highly addictive and deadly substances that are of dubious use for treating the long-term, chronic pain suffered by so many players, and fining and suspending players who choose instead to self-medicate with a less-addictive and non lethal substance. The disproportionality of the league’s substance abuse policy was put into stark relief in 2015, when the Browns’ Josh Gordon received a year-long suspension for multiple violations of the league’s marijuana ban. When Ravens running back Ray Rice was charged with aggravated assault for beating his then-fiancee, his initial suspension from the league was only two games.

0 2523

The biotech sector will be one of the greatest beneficiaries of the global cannabis movement and is comprised of some of the most mature and best capitalized companies.

The Nasdaq was the worst performing exchange yesterday and biotech cannabis-focused firms traded lower on average. Although we continue to be bullish on this sub-sector of the cannabis industry, it is also the one that would be most impacted by a correction in the market.

This sector is comprised of some of most attractive long-term companies. We think recent weakness has created opportunity and we want to highlight five cannabis stocks every investor should be watching.

Insys Therapeutics (INSY) traded in a very volatile range after reporting its fourth quarter and full year financial results yesterday. Insys opened down almost 5% and the shares traded as low as $10.01 before finding support. INSY bounced off these lows and the shares ended the day up 2.2%. INSY is at $10.75 and Technical420 plans to average down and add to its position if the shares trade below $10. The shares are trading well below its average Wall Street price target (more than 60% upside to average price target). One of the main reasons why we are favorable on Insys is because we view the company as an acquisition candidate due to its valuable intellectual property and relatively cheap valuation.
Corbus Pharmaceuticals (CRBP) gave up all its gains from Monday and the shares are trading at $8.05 after a 2.4% move lower on weak volume. We continue to monitor CRBP from the sidelines after exiting our position within hours of entering. We are on the sidelines due to the misleading reports, the increased volatility, and the potential for the market to dip lower in the near term.
Cara Therapeutics (CARA) was under pressure yesterday and the shares are trading below the pricing of its recently announced financing. Technical420 remains favorable on Cara Therapeutics and see significant upside to current levels. The shares are trading at $17.92 after a 2.5% move lower and we plan to add to our position on continued weakness. Cara plans to use the proceeds from its $80 million raise to fund clinical and R&D activities, including the completion of the Phase 3 program in uremic pruritus, two Phase 3 trials in acute pain and a Phase 2b trial in osteoarthritis pain. We will keep you updated on how the shares trade today.
GW Pharmaceutical (GWPH) edged lower on light volume yesterday and the shares are currently trading below its 20 and 50-day moving average. GWPH has fallen 8% in the last month and we view the shares as an attractive long-term opportunity at current levels. GW has one of the deepest pipelines of products in advanced stages of FDA testing. The company also has the best Wall Street coverage and has received buy ratings from Goldman Sachs, Merrill Lynch, and Morgan Stanley. We view GW as an acquisition candidate and Goldman Sachs estimated a $390 a share acquisition price if that was to occur. From the filing of a New Drug Application to multiple Phase 3 Clinical trials, GW Pharma is an event-driven story that has many potential catalysts. We plan to hold and add to our position on continued weakness.
Zynerba Pharmaceuticals (ZYNE) continues to be one of the most attractive cannabis biotech investment opportunities due to the relatively cheap valuation, its high-quality pipeline of products, the number of upcoming catalysts, and its favorable and improving Wall Street coverage. In late March, H.C. Wainwright raised Zynerba’s price target to $30 from $22. The average price target on shares of Zynerba is north of $30 and offers more than 50% upside to current levels.

0 1157
cbd stocks

Two marijuana reform bills were recently signed by Virginia Governor Terry McAuliffe (D), ending the state’s automatic six-month driver’s license suspension for first time possession offenders and allowing the production of CBD oil. This may look like a couple drops in a raging storm of national decriminalization, but NORML Executive Director, Erik Altieri, said it’s a huge accomplishment.

Altieri stated, “The two measures signed into law in Virginia this week may seem like baby steps, but they are the culmination of years of dedicated advocacy and legislative outreach. While neither of these bills will end the arrest of around 18,000 Virginians a year for marijuana possession or create an ideal, accessible medical marijuana program, they represent important progress in terms of growing legislative support for marijuana law reforms.”

When Senate Bill 1091 (which ends Virginia’s automatic ID suspension penalty) goes into effect at the beginning of July, it will be left at the court’s discretion whether or not to impose this condition as a term of probation, and convicts will still be subject to other conditions under Virginia law, including substance abuse screening, drug testing and community service. Minors are still subject to automatic license suspension under the new law.

For many years Virginia has all but topped the list of places you didn’t want to be caught with marijuana. In recent years Virginia has seen quite the increase in enforcement. According to data collected by the Drug Policy Alliance, marijuana possession arrests increased from approximately 13,000 in 2003 to almost 23,000 in 2014, an increase that was especially pronounced in majority Black neighborhoods.

Now that McAuliffe’s put pen to paper, the state should begin to see continued progress in this area, which has already seen some improvement since 2014. This past December, Newport News reported that the number of people arrested or charged with marijuana offenses had fallen by 14% statewide over a two-year stretch. This is step in the right direction, but putting real decriminalization laws on the books is the real answer to ending the waste and social destruction of cannabis prohibition. Keeping strict laws on the books but applying lenient, quasi-enforcement standards creates the potential for serious trouble.

Under “selective enforcement,” those who are most affected and targeted by law enforcement now; communities of colors would continue to carry that burden. In the three years from 2011 to 2013, marijuana possession arrests increased by 1,987 in Virginia; black people accounted for 82% of that increase. The Marijuana Policy Project referred to SB 1027 as an “extremely narrow law.” It will allow those suffering from intractable epilepsy to access CBD oils produced in state by Department of Health-approved pharmaceutical companies.

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements